PolyPid (PYPD) Scheduled to Post Earnings on Wednesday

PolyPid (NASDAQ:PYPD) is set to issue its quarterly earnings data before the market opens on Wednesday, November 13th. Analysts expect the company to announce earnings of ($1.07) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

PolyPid (NASDAQ:PYPD) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($1.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.51) by $0.26. On average, analysts expect PolyPid to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

PolyPid Price Performance

Shares of PYPD stock opened at $3.34 on Wednesday. The firm has a fifty day simple moving average of $3.48 and a 200-day simple moving average of $3.87. The company has a market capitalization of $16.02 million, a PE ratio of -0.33 and a beta of 1.31. PolyPid has a twelve month low of $2.95 and a twelve month high of $9.20. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 1.95.

Wall Street Analyst Weigh In

A number of research firms have weighed in on PYPD. Craig Hallum started coverage on shares of PolyPid in a research report on Monday. They issued a “buy” rating and a $10.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $14.00 price target on shares of PolyPid in a report on Wednesday, October 2nd.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.